Ligand Evolution in the Photoactivatable Platinum(IV) Anticancer Prodrugs

Jingjing Huang; Weize Ding; Xingfan Zhu; Bingbing Li; Fangang Zeng; Kui Wu; Xiaoqin Wu; Fuyi Wang

doi:10.3389/fchem.2022.876410

Ligand Evolution in the Photoactivatable Platinum(IV) Anticancer Prodrugs

Front Chem. 2022 Jun 9:10:876410. doi: 10.3389/fchem.2022.876410. eCollection 2022.

Authors

Jingjing Huang¹, Weize Ding¹, Xingfan Zhu¹, Bingbing Li¹, Fangang Zeng², Kui Wu¹, Xiaoqin Wu¹, Fuyi Wang^{3

4

5}

Affiliations

¹ Key Laboratory of Hubei Province for Coal Conversion and New Carbon Materials, School of Chemistry and Chemical Engineering, Wuhan University of Science and Technology, Wuhan, China.
² School of Environment and Natural Resources, Renmin University of China, Beijing, China.
³ College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
⁴ Beijing National Laboratory for Molecular Sciences, National Centre for Mass Spectrometry in Beijing, CAS Key Laboratory of Analytical Chemistry for Living Biosystems, Institute of Chemistry, Chinese Academy of Sciences, Beijing, China.
⁵ University of Chinese Academy of Sciences, Beijing, China.

Abstract

Photoactivatable Pt(IV) anticancer prodrugs with the structure of [Pt^IV(N₁)(N₂)(L₁)(L₂)(A₁)(A₂)], where N₁ and N₂ are non-leaving nitrogen donor ligands, L₁ and L₂ are leaving ligands, and A₁ and A₂ are axial ligands, have attracted increasing attention due to their promising photo-cytotoxicity even to cisplatin-resistant cancer cells. These photochemotherapeutic prodrugs have high dark-stability under physiological conditions, while they can be activated by visible light restrained at the disease areas, as a consequence showing higher spatial and temporal controllability and much more safety than conventional chemotherapy. The coordinated ligands to the Pt center have been proved to be pivotal in determining the function and activity of the photoactivatable Pt(IV) prodrugs. In this review, we will focus on the development of the coordinated ligands in such Pt(IV) prodrugs and discuss the effects of diverse ligands on their photochemistry and photoactivity as well as the future evolution directions of the ligands. We hope this review can help to facilitate the design and development of novel photoactivatable Pt(IV) anticancer prodrugs.

Keywords: anticancer; ligand; photoactivatable; platinum(IV) prodrug; structure–activity relationship.

Publication types

Review